THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY

被引：0

作者：

Nuijten, M. ^{[1
]}

机构：

[1] Ars Accessus Med, Jisp, Netherlands

来源：

VALUE IN HEALTH | 2009年 / 12卷 / 03期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A41 / A41

页数：1

共 50 条

[1] A cost effectiveness analysis of bevacizumab plus cisplatin and gemcitabine (BCG) compared with induction pemetrexed plus cisplatin (iPC) for the treatment of advanced or recurrent non-small cell cancer (NSCLC) in Germany
Bischoff, Helge
Heigner, David
Wiesner, Christof
Walzer, Stefan
[J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S666 - S667
[2] An incremental cost-consequence analysis of bevacizumab plus cisplatin and gemcitabine (BCG) compared with induction pemetrexed plus cisplatin (PC) in patients with advanced or recurrent non-small cell cancer (NSCLC) in Italy
de Marinis, Filippo
Grossi, Francesco
Giuliani, Giovanni
Aultman, Rick
[J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S676 - S677
[3] Analysis of cost-effectiveness of Bevacizumab plus cisplatin and gemcitabine (BCG) compared to an induction therapy with pemetrexed plus cisplatin (PC) in advanced or recurrent non-small cell lung cancer (NSCLC)
Bischoff, H.
Heigener, D.
Wiesner, C.
Walzer, S.
[J]. ONKOLOGIE, 2010, 33 : 131 - 132
[4] A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Bischoff, H. G.
Heigener, D.
Wiesner, C.
Walzer, S.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A273 - A273
[5] The cost-effectiveness of bevacizumab plus cisplatin and gemcitabine (BCG) compared with pemetrexed plus cisplatin (PC) induction treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in Germany.
Bischoff, H.
Hermes, A.
Gatzemeier, U.
Heigener, D. F.
Cesaro-Tadic, S.
Walzer, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[6] COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY - AN UPDATED ANALYSIS
Bischoff, H. G.
Hermes, A.
Heigener, D. F.
Cesaro-Tadic, S.
Walzer, S.
Nuijten, M.
[J]. VALUE IN HEALTH, 2010, 13 (03) : A39 - A39
[7] COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Heigener, D.
Bischoff, H. G.
Wiesner, C.
Aultman, R.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A263 - A264
[8] An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)
Walzer, S.
de Castro Carpeno, J.
Vergnenegre, A. V.
Chouaid, C.
Heigener, D. F. H.
Bischoff, H. G.
Nicolson, M. C.
Aultman, R.
Siebert, U.
[J]. EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555
[9] A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) in Germany
Heigener, D. F.
Wiesner, C.
Aultman, R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[10] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Scagliotti, Giorgio
Purvish, Parikh
von Pawel, Joachim
Biesma, Bonna
Vansteenkiste, Johan
Manegold, Christian
Simms, Lorinda
Posther, Sugarman Katherine
Obasaju, Coleman
Blatter, Johannes
[J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S306 - S306

← 1 2 3 4 5 →